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Acinetobacter baumannii is an important cause of nosocomial infections in many hospitals.
It is difficult to control and infection caused is difficult to treat due to its high resistance in
the environment and its ability to develop resistance to antimicrobials. Bacteremia,
followed by respiratory tract and surgical wound infections, is the most significant
infection caused by A. baumannii. The known risk factors for A. baumannii bacteremia are
invasive procedures and the use of broad-spectrum antimicrobials. Consequently,
episodes of bacteremia due to A. baumannii occur most frequently in critically-ill patients
admitted to an intensive care unit. The clinical manifestations of bacteremia by A.
baumannii are not specific. The most common sources of bacteremia are intravascular
catheters and the respiratory tract. A. baumannii bacteremia is associated with a high
crude mortality rate, but it is difficult to distinguish morbidity and mortality attributable
to A. baumannii from that attributable to the common and severe co-morbidity in these
patients. A. baumannii is a bacterium that appears to have a propensity for developing
multiple antimicrobial resistance extremely rapidly. These data are disturbing because
the therapeutic possibilities decrease while inappropriate antimicrobial treatment con-
tributes to patient mortality. Generally, imipenem is the most active agent against A.
baumannii. However, the description of imipenem-resistant A. baumannii strains is
becoming increasingly common. The usual treatment for A. baumannii bacteremia is
an active b-lactam alone, preferably one with a limited spectrum. Before beginning
treatment of a bacteremia by A. baumannii, it is very important to carry out a clinical
evaluation of the patient to eliminate the possibility of a pseudobacteremia, and thereby
avoid unnecessary treatment.
I N T R O D U C T I O N
In 1986 a new taxonomy was established for the
Acinetobacter genus, of which A. baumannii is the
most frequent species in clinical samples [1]. Since
then A. baumannii has become a formidable patho-
gen and has been responsible for a number of no-
socomial infection outbreaks. It is difficult both to
control and infection caused is difficult to treat due
to its high resistance in the environment and its
ability to develop resistance to antimicrobials [2,3].
Bacteremia, followed by respiratory tract and
surgical wound infections, is the most significant
infection caused by A. baumannii. Its incidence
varies considerably depending on periods of
epidemic outbreak and the medical center itself
[4–10]. Beck-Sague´ et al. relate an incidence of 17
episodes per 1000 admissions during an epidemic
outbreak [4]. However, Tilley et al. report an
incidence of 0.3 episodes per 100 admissions when
there is no epidemic [9]. In two large hospitals in
Seville (Spain), the incidence of A. baumannii bac-
teremia has been variable, from 1.85 episodes per
1000 admissions in 1993 [7], to 0.6 episodes per
1000 admissions in 2000, and from 1.2 episodes per
1000 admissions between 1995 and 1997 [10] to
0.02 episodes in 1999.
Bacteremia due to A. baumannii is characteristi-
cally a nosocomial infection, particularly in inten-
sive care units (ICUs). It is opportunistic and
therefore almost exclusively affects predisposed
patients who have undergone invasive procedures
[5–7]. The known risk factors for A. baumannii
colonization/infection are prolonged hospital
stay, ICU stay, previous admission to another unit,
enteral feeding and previous use of third-genera-
tion cephalosporins [11,12].
 2002 Copyright by the European Society of Clinical Microbiology and Infectious Diseases
Corresponding author and reprint requests: Jose´ Miguel
Cisneros, Servicio de Enfermedades Infecciosas, Hospital
Universitario Virgen del Rocı´o, Sevilla, Spain
E-mail: jcisnerosh@medynet.com
E P I D E M I O L O G Y A N D R I S K
F A C T O R S
At the time of writing, A. baumannii is an important
cause of nosocomial infections in many hospitals.
Numerous outbreaks caused by a single clone
have been reported, but the situation in most
centers would be more appropriately described
as endemic. In these hospitals, no more than 10–
30% of patients from whom A. baumannii is
isolated have bacteremia. Thus, the incidence of
A. baumannii bacteremia in these hospitals
should only be considered as the tip of the iceberg
regarding the epidemiological situation of the
organism.
Data from published studies showed some of
the epidemiological features of A. baumannii. It is
able to survive for long periods of time on inan-
imate surfaces in the patients’ vicinity [13]. Envir-
onmental contamination is important as the
organism can be transmitted from these surfaces
to patients directly or through the hands of health-
care workers. In addition, colonized and infected
patients also represent an important reservoir of A.
baumannii [14]. The organism may also be trans-
mitted from patient to patient. In fact, the number
of colonized patients has been described as the
main risk factor for the acquisition of the organism
by other patients admitted to the same unit or
ward [15]. Health-care workers are usually only
transiently colonized. Molecular analysis has
demonstrated that the nosocomial infections
caused by this organism within a hospital may
be due both to epidemic and sporadic clones, and
that the risk factors for the acquisition of epidemic
or sporadic clones may be different [16].
Even though outbreaks caused by A. baumannii
have been described in medical and surgical
wards, ICUs are the most frequently affected areas.
Colonization may be subsequently followed by an
invasive infection [14]. In burn patients, previous
colonization was strongly associated with the
acquisition of bacteremia [17]. The potential risk
factors for the development of bacteremia in other
patients are invasive procedures (central venous
catheterization, mechanical ventilation, surgery)
and the use of broad spectrum antimicrobials.
Consequently, episodes of bacteremia due to A.
baumannii occur most frequently in critical patients
admitted to an ICU [5,7], as these patients usually
need more invasive procedures for longer periods
of time, and frequently receive treatment with
antimicrobials. In a multicenter study performed
in the USA, patients with nosocomial bloodstream
infections due to Acinetobacter spp., compared with
patients with nosocomial bacteremia due to other
Gram-negative pathogens, were more frequently
in the ICU and were more frequently receiving
mechanical ventilation [18]. Identified specific risk
factors for A. baumannii bacteremia in ICU patients
are immunosuppression, unscheduled admission,
respiratory failure at ICU admission, previous
antimicrobial therapy, previous sepsis and the
high invasive-procedures index [19]. Neonatal
ICUs may also be affected [20].
Microbiological typing has been performed in
some studies dealing with bloodstream infections
due to this organism. Beck-Sague´ et al. described
an outbreak of A. baumannii bacteremia in five
ICUs associated with the use of contaminated
pressure transducers [4]. Isolates cultured from
pressure transducers and isolates cultured from
the patients were identical in plasmid profiles.
This technique was useful for presumptively iden-
tifying the source of the outbreak, which was
controlled when the transducers were correctly
sterilized. In another study, 87 episodes occurring
in 79 patients in an 18-month period were
reviewed [5]. Epidemiological molecular typing
using pulsed-field gel electrophoresis revealed
11 different A. baumannii strains. The results of
this study reflect a more complex situation, in
which the episodes of bloodstream infections are
caused both by epidemic and sporadic strains: 45,
21, eight and three episodes were caused by four
epidemic strains, while the rest of the episodes
were caused by sporadic strains. A. baumannii
epidemic strains were also found in five hospitals
in the multicenter study by Wisplinghoff et al. [18].
Interhospital spread of epidemic strains was not
observed in that study.
A seasonal variation has been reported in noso-
comial Acinetobacter infections, and in bacteremia
in particular, with an increase in the incidence
during the summer months [21]. Changes in tem-
perature and humidity have been proposed as a
possible explanation. The possible influence of
decreased staff during summer months has not
been studied.
C L I N I C A L M A N I F E S T A T I O N S
The clinical aspects of A. baumannii are not as well
known as the epidemiological aspects and may
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sometimes be confusing, as they are often grouped
with other Acinetobacter species [5–9]. The clinical
manifestations of bacteremia by A. baumannii are
not specific. It may present as a transitory macu-
lopapular rash affecting the palms of the hands
and the soles of the feet in endocarditis patients
[22], or as necrotic lesions of the skin and soft tissue
[23]. Bacteremia by A. baumannii is often polymi-
crobial (19–35% of the cases) [5,7].
The most common sources of bacteremia by A.
baumannii are intravascular and respiratory tract
catheter [4,5,7]. An origin from surgical wounds,
burns and the urinary tract is less common, and is
very rare from endocarditis [5–8,22]. In up to 21–
70% of the episodes, the origin of the bacteremia is
unknown [6–8]. Some of these primary bactere-
mias could be secondary to undiagnosed vascular
catheter infections or have an intestinal origin due
to bacterial translocation. This is supported by the
demonstration that digestive tract colonization by
A. baumannii is more frequent and advanced in
ICU patients [14,24].
The prognosis for bacteremia by A. baumannii is
controversial. On one hand, its clinical relevance is
under question, as the organism has few known
virulence factors. On the other hand, clinical stu-
dies point out that bacteremia by A. baumannii
results in septic shock in 25–30% of cases and that
disseminated intravascular coagulation is also
common [5,7].
A N T I M I C R O B I A L R E S I S T A N C E
A. baumannii is a bacterium that appears to have a
propensity for developing antimicrobial resistance
extremely rapidly. Moreover, this resistance is
multiple, causing serious therapeutic problems.
Practices in ICUs contribute to the development
of antimicrobial resistance in A. baumannii because
the use of antimicrobials per patient and per sur-
face area are significantly higher in this part of the
hospital.
Susceptibility of A. baumannii to antimicrobials
is considerably different among countries, among
centres and even among the wards of a given hos-
pital.Thesedifferencesmayreflectdifferentpatterns
of antimicrobial usage and different epidemiolog-
ical situations, including antimicrobial control mea-
sures and policies. The differences in resistance
patterns among isolates emphasize the importance
of local surveillance in determining the most
adequate therapy for A. baumannii infections.
The known resistance mechanisms of A. bau-
mannii to antimicrobials are: the production of
broad-spectrum b-lactamases, aminoglycoside-
modifying enzymes, changes in outer membrane
porins and alterations in penicillin-binding pro-
teins (PBP). Antimicrobial resistance has been
tracked to plasmids, transposons and chromo-
somes [25].
Generally, imipenem is the most active agent
against A. baumannii. In one study carried out in 49
US hospitals, in which 111 episodes of bacteremia
by A. baumannii were analyzed, imipenem was
active in vitro (CMI90 1 mg/L; 100% of the sus-
ceptible isolates) [17]. However, the description of
imipenem-resistant A. baumannii strains is increas-
ingly more common [7,19–23,26]. In our hospital in
1991, 100% of the A. baumannii isolates in blood
were susceptible to imipenem, whereas in the year
2000, 50% were resistant to this antimicrobial.
Urban et al. previously described the appearance
of imipenem resistance following the increased
use of this antimicrobial to treat an outbreak of
nosocomial infections by Acinetobacter sp. The iso-
lates of imipenem-resistant A. baumannii are often
multidrug resistant [27].
The development of resistance to antimicro-
bials in A. baumannii appears to be unstoppable.
In 1993 five isolates, two in blood, which were
only resistant to colistin were described [28]. These
data are disturbing because the therapeutic pos-
sibilities decrease while patient mortality increas-
es with inappropriate antimicrobial treatment
[7,29].
P R O G N O S I S
In general, A. baumannii bacteremia is associated
with a high crude mortality rate, but it is difficult to
distinguish between morbidity and mortality attri-
butable to A. baumannii and that attributable to co-
morbidity, which is common and severe in these
patients.
The data from some prognostic studies on ICU
patients suggest that infection by A. baumannii,
particularly pneumonia, increases mortality and
prolongs hospital stay [30–32].
However, the prognosis of bacteremia by A.
baumannii is still unclear. Previous studies, includ-
ing the one carried out by our group, confirm that
the crude mortality rate is high, fluctuating
between 17% and 52%; and the factors indepen-
dently associated with poor prognosis are the
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severity of the underlying disease, pneumonia as
the source of bacteremia, septic shock, dissemi-
nated intravascular coagulation, mechanical ven-
tilation, and inappropriate antimicrobial treatment
[5–9]. In contrast, bacteremias originating from
vascular catheters and bacteremias caused by
non-baumannii Acinetobacter were associated with
lower mortality [7,18,33,34]. The preliminary
results of a prospective study of cases and controls
aiming to establish a prognosis for nosocomial A.
baumannii bacteremia suggest that high mortality
in these patients is not due to the bacteremia, but to
co-morbidity, whereas prolonged hospital stay is
related to the bacteremia itself [35].
T R E A T M E N T
The treatment of choice for A. baumannii bacter-
emia has not been established. There have been no
comparative therapeutic trials, and clinical experi-
ence is lacking. The usual treatment is an active b-
lactam alone or an association with to an amino-
glycoside, similar to the treatment for bacteremia
caused by other Gram-negative bacilli [25].
Imipenem treatment resulted in cure of the
bacteremia in 83% of the cases in one study [7].
There are no clinical studies comparing the effi-
ciency of monotherapy with a b-lactam and ther-
apy in combination with an aminoglycoside.
Synergy between an imipenem b-lactam inhibitor
and an aminoglycoside has been reported in the
in vitro studies [36]. However, experimental stu-
dies suggest that the addition of aminoglycoside
does not improve the results obtained by imipe-
nem monotherapy. Rodrı´guez-Herna´ndez et al.
reported that monotherapy with imipenem is as
effective as therapy with imipenem plus amikacin
in the treatment of experimental A. baumannii
pneumonia [37].
Sulbactam is an inhibitor of b-lactamase, which
shows in vitro bactericidal activity against Acine-
tobacter sp. [38–41]. Rodrı´guez-Herna´ndez et al.
showed that the efficacy of sulbactam in experi-
mental infections caused by susceptible A. bauman-
nii strains was similar to that of imipenem [42].
Serum and cerebrospinal fluid levels (in patients
with meningitis) of sulbactam average 68 mg/L
and 8.5 mg/mL, respectively, when 1 g is given
intravenously. Sulbactam has initially been used
along with ampicillin in the treatment of 10
patients with infections caused by Acinetobacter
sp. resistant to imipenem, nine of whom improved
clinically [27]. Corbella et al. treated 42 patients
with non-life-threatening multiresistant A. bau-
mannii infections, including seven bacteremias,
with sulbactam alone and in combination with
ampicillin (1 g every 8 h); 39 improved or were
cured with no major adverse affects. In this study,
killing curves showed that sulbactam was bacter-
iostatic [43]. Also, sulbactam may be effective as
therapy for bacteremia with meningitis caused by
multidrug-resistant A. baumannii. Jime´nez-Mejı´as
et al. cured six out of eight patients with nosoco-
mial A. baumannii meningitis treated with sulbac-
tam (1 g every 6–8 h) [44]. One retrospective
analysis compared treatment outcomes of 48
patients with A. baumannii bacteremia treated with
imipenem or ampicillin–sulbactam. Ampicillin–
sulbactam was at least as effective as imipenem
and was a cost-effective alternative for treatment
[45]. Finally, we described the cure of seven out of
eight patients (87%) with A. baumannii bacteremia
following treatment with sulbactam [7]. These data
support the recommendation of sulbactam treat-
ment (1 g given intravenously each 6–8 h for 10–
14 days) for A. baumannii bacteremia whenever the
organism is susceptible to this antimicrobial
(Table 1).
Unfortunately, resistance to sulbactam has been
noted in imipenem-resistant strains of A. bauman-
nii, leaving the polymyxins (colistimethate and
polymyxin B) as the only treatment alternative
[28]. Colistin was used in the 1960s and 1970s
but was abandoned due to adverse side-effects,
mainly nephrotoxicity, neurotoxicity and neuro-
Table 1 Antimicrobials recommended for the treatment of
bacteremia due to A. baumannii
Bacteremia due to non-multiresistant A. baumannii
an active betalactam according to antibiogram,
preferably one with reduced spectrum
(example: sulbactam> aztreonam> ceftazidime>
imipenem)
Bacteremia due to multiresistant A. baumannii
Choice: sulbactam 1 g intravenously every 6–8 h
Alternative: imipenem 500 mg intravenously every 6 h
(multiresistant Acinetobacter spp. is habitually only
susceptible to imipenem)
If meningitis-associated: meropenem 1 g intravenously
every 8 h
Bacteremia by imipenem-resistant A. baumannii
Sulbactam 1 g intravenously every 6–8 h
Bacteremia by ‘pan-resistant’ A. baumannii
Colistin 2.5–5 mg/kg/day intravenously in two or three
doses
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muscular blockage, and because of the emergence
of newer and safer antimicrobials. Through a
poorly understood mechanism of action, colistin
breaks the bacterial wall and is active against
many Gram-negative bacteria, but not against
Gram-positive rods. Colistin scarcely penetrates
through the blood–brain barrier. Go et al. first
used polymixin B, applied topically, in the treat-
ment of infections by imipenem-resistant A. bau-
mannii. Infection and colonization were eliminated
by intensive infection control measures, and irri-
gation of wounds with polymixin B [46]. Levin
et al. reported the outcomes of 60 nosocomial
infections, including bacteremia, caused by A.
baumannii and Pseudomonas aeruginosa which were
resistant to all commercially available antimicro-
bial agents, treated with colistin [47]. The patients
were treated with 2.5–5.0 mg of colistin/kg daily
up to a maximum dose of 300 mg, which was
divided into two or three intravenous doses. When
the patients presented with renal failure, the daily
dose was adjusted: serum creatinine level from 1.3
to 1.5 mg/dL, daily dose of 2.5–5.0 mg/kg; 1.6–
2.5 mg/dL, 2.5 mg/kg; and >2.5 mg/dL, 1.0–
1.5 mg/kg. The mean duration of treatment was
14 days (5–25 days). There was a good outcome for
58% of the patients in general, but for only 25% of
the patients with pneumonia. The main adverse
effect of treatment was renal failure (27% in
patients with initially normal renal function, and
58% in patients with initially abnormal renal func-
tion), however treatment was not discontinued
because of nephrotoxicity and no neuromuscular
disorders were observed.
The results of this study make it possible to
recommend colistin (2.5–5 mg/kg/day intrave-
nously for 14 days) for treating patients with A.
baumannii bacteremia who have no other thera-
peutic options. It is necessary to adjust the dose for
patients with altered renal function and to monitor
them closely.
Other in vitro studies showed that rifampicin in
conjunction with either colistin or sulbactam was
synergic against multidrug-resistant strains of A.
baumannii, and suggest that that combination may
be effective therapy for patients with severe infec-
tions caused by multidrug-resistant strains of A.
baumannii [48,49].
Before beginning treatment of an A. baumannii
bacteremia, it is very important to carry out a
clinical evaluation of the patient to eliminate the
possibility of a pseudobacteremia, diagnosed due
to incorrect collection or handling of the blood
culture, and thereby avoid unnecessary treatment.
Furthermore, it is important to try to establish the
origin of the bacteremia, making its elimination
possible. Removal of the intravascular catheter, or
other foreign body, and surgical treatment of the
source of the bacteremia whenever possible, are
indicated.
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